Biocodex
France - GentillyBiotechnology
Focus: Biocodex is a France-based biotechnology company specializing in microbiota treatments, with a primary focus on neurology applications. The company derives 50% of revenue from its flagship product DIACOMIT (stiripentol) for Dravet Syndrome.
Profile data last refreshed 2d ago · AI intelligence enriched 2w ago
Open Jobs
0
About Biocodex
AI assessmentNot HiringNo open roles listed right now. Follow Biocodex to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
3/9 — Basic
Company HealthStrong
Pipeline
Late-stage
4 Phase 3+
LOE Risk
2 in 5yr
DIACOMIT
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$1M Part DStable
Peak3.2yr
Flagship product representing 50% of company revenue with peak sales phase but facing patent expiration in 5 years.
Help build intelligence for Biocodex
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.